Eli Lilly will cut the price of its most commonly prescribed insulin products by 70% and expand a program that caps patient costs at $35 per month, the company said on Wednesday. "While the current ...

Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). The company overtook early GLP-1 leader Novo Nordisk. Eli Lilly is increasingly reliant on its GLP-1 drugs.

INDIANAPOLIS — Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions. The moves announced Wednesday promise ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, ...

Eli Lilly, in the race to develop the first major oral GLP‑1 drug for weight loss, says its pill orforglipron will be submitted for approval this year after a Phase 3 study found it delivered ...

Eli Lilly could extend its lead in its core therapeutic area with the launch of two new products next year. The company also ...

The European Medicines Agency's committee on Friday recommended extending ‍the use of Eli Lilly's blockbuster drug Mounjaro ...

Eli Lilly's popular drug Mounjaro will be added to China's state-run health insurance scheme from January 1 for patients with ...